4.7 Article

A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia

期刊

BLOOD
卷 115, 期 12, 页码 2462-2472

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2009-08-239822

关键词

-

资金

  1. National Cancer Institute [CA101140]
  2. Leukemia Clinical Research Foundation
  3. Cancer Research Society Canada
  4. Cole foundation

向作者/读者索取更多资源

The GFI1 gene encodes a transcriptional repressor, which regulates myeloid differentiation. In the mouse, Gfi1 deficiency causes neutropenia and an accumulation of granulomonocytic precursor cells that is reminiscent of a myelodysplastic syndrome. We report here that a variant allele of GFI1 (GFI1(36N)) is associated with acute myeloid leukemia (AML) in white subjects with an odds ratio of 1.6 (P < 8 x 10(-5)). The GFI136N variant occurred in 1806 AML patients with an allele frequency of 0.055 compared with 0.035 in 1691 healthy control patients in 2 independent cohorts. We observed that both GFI1 variants maintain the same activity as transcriptional repressors but differ in their regulation by the AML1/ETO (RUNX1/RUNX1T1) fusion protein produced in AML patients with a t(8;21) translocation. AML1/ETO interacts and colocalizes with the more common GFI1(36S) form in the nucleus and inhibits its repressor activity. However, the variant GFI1(36N) protein has a different subnuclear localization than GFI1(36S). As a consequence, AML1/ETO does not colocalize with GFI1(36N) and is unable to inhibit its repressor activity. We conclude that both variants of GFI1 differ in their ability to be regulated by interacting proteins and that the GFI1(36N) variant form exhibits distinct biochemical features that may confer a predisposition to AML. (Blood. 2010;115:2462-2472)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Hematology

Germ line DDX41 mutations define a unique subtype of myeloid neoplasms

Hideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, Sophia Korotev, Carmelo Gurnari, June Takeda, Yukihide Momozawa, Steve Best, Pramila Krishnamurthy, Tetsuichi Yoshizato, Yoshiko Atsuta, Yusuke Shiozawa, Yuka Iijima-Yamashita, Kenichi Yoshida, Yuichi Shiraishi, Yasunobu Nagata, Nobuyuki Kakiuchi, Makoto Onizuka, Kenichi Chiba, Hiroko Tanaka, Ayana Kon, Yotaro Ochi, Masahiro M. Nakagawa, Rurika Okuda, Takuto Mori, Akinori Yoda, Hidehiro Itonaga, Yasushi Miyazaki, Masashi Sanada, Takayuki Ishikawa, Shigeru Chiba, Hisashi Tsurumi, Senji Kasahara, Carsten Mueller-Tidow, Akifumi Takaori-Kondo, Kazuma Ohyashiki, Toru Kiguchi, Fumihiko Matsuda, Joop H. Jansen, Chantana Polprasert, Piers Blombery, Yoichiro Kamatani, Sator Miyano, Luca Malcovati, Torsten Haferlach, Michiaki Kubo, Mario Cazzola, Austin G. Kulasekararaj, Lucy A. Godley, Jaroslaw P. Maclejewski, Seishi Ogawa

Summary: DDX41 gene mutations play an important role in late-onset myeloid neoplasms, but many crucial features of DDX41-mutated neoplasms still need to be elucidated. This study comprehensively characterized DDX41-mutated neoplasms and found that DDX41 risk variants accounted for 80% of known genetic predispositions to myeloid neoplasms in adults. Additionally, DDX41 risk alleles were significantly enriched in Japanese cases and more prominent in males compared to females.
Article Cardiac & Cardiovascular Systems

Clonal haematopoiesis of indeterminate potential: associations with heart failure incidence, clinical parameters and biomarkers

Canxia Shi, Joseph Pierre Aboumsallem, Navin Suthahar, Aniek O. de Graaf, Joop H. Jansen, Isabelle A. van Zeventer, Valentina Bracun, Sanne de Wit, Elles M. Screever, Pieter F. van den Berg, Wouter C. Meijers, Ron T. Gansevoort, Stephan J. L. Bakker, Pim van der Harst, Herman H. W. Sillje, Gerwin Huls, Rudolf A. de Boer

Summary: This study aimed to analyze the association between clonal hematopoiesis of indeterminate potential (CHIP) and incident heart failure (HF) in a European population cohort. Results showed that CHIP mutations were correlated with age, smoking, hypertension, and cardiovascular biomarkers, but the frequency of CHIP was similar between individuals with incident HF and control participants. However, among people younger than 65 years, CHIP mutations were more frequently detected in the case cohort and significantly associated with new-onset HF.

EUROPEAN JOURNAL OF HEART FAILURE (2023)

Article Hematology

Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study

Carin L. E. Hazenberg, Aniek O. de Graaf, Rene Mulder, Laura B. Bungener, Andre B. Mulder, Goda Choi, Jan Jacob Schuringa, Marco R. de Groot, Edo Vellenga, Joop H. Jansen, Gerwin Huls, Isabelle A. van Zeventer

Summary: Inadequate mobilization of peripheral blood progenitor cells (PBPCs) is a limiting factor in autologous hematopoietic cell transplantation (auto-HCT). A study investigated the characteristics of poor mobilizers and the impact of clonal hematopoiesis (CH) on mobilization failure. The presence of CH did not associate with poor mobilization potential, but TP53 mutations and PPM1D mutations were associated with poor mobilization potential.

BLOOD ADVANCES (2023)

Article Hematology

Overlapping features of therapy-related and de novo NPM1-mutated AML

Jad Othman, Manja Meggendorfer, Enrico Tiacci, Christian Thiede, Richard Schlenk, Richard Dillon, Sebastian Stasik, Alessandra Venanzi, Sarah Bertoli, Eric Delabesse, Pierre-Yves Dumas, Arnaud Pigneux, Audrey Bidet, Amanda F. Gilkes, Ian Thomas, Maria Teresa Voso, Alessandro Rambaldi, Lorenzo Brunetti, Vincenzo M. Perriello, Vibeke Andresen, Bjorn T. Gjertsen, Maria Paola Martelli, Christian Recher, Christoph Roellig, Martin Bornhaeuser, Hubert Serve, Carsten Mueller-Tidow, Claudia D. Baldus, Tortsten Haferlach, Nigel Russell, Brunangelo Falini

Summary: The characteristics of therapy-related NPM1-mutated AML (t-NPM1 AML) were found to be similar to de novo NPM1-mutated AML (dn-NPM1 AML) in terms of genetics, transcriptional profile, and clinical outcomes. However, t-NPM1 AML showed better overall survival and relapse-free survival compared to t-AML.
Letter Hematology

Sex Differences in the Spectrum of Clonal Hematopoiesis

Priscilla Kamphuis, Isabelle A. A. van Zeventer, Aniek O. O. de Graaf, Jonas B. B. Salzbrunn, Maaike G. J. M. van Bergen, Avinash G. G. Dinmohamed, Bert A. A. van der Reijden, Jan Jacob Schuringa, Joop H. H. Jansen, Gerwin Huls

HEMASPHERE (2023)

Article Hematology

Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population

Priscilla Kamphuis, Maaike G. J. M. van Bergen, Isabelle A. van Zeventer, Aniek O. de Graaf, Avinash G. Dinmohamed, Jonas B. Salzbrunn, Jan Jacob Schuringa, Bert A. van der Reijden, Gerwin Huls, Joop H. Jansen

Summary: Clonal hematopoiesis (CH) may increase the risk of hematological malignancies and overall survival in individuals with platelet count abnormalities. Thrombocytopenia cases showed enrichment of mutations in spliceosome genes, while thrombocytopenia with multiple mutated genes (TP53 or spliceosome genes) increased the risk of death. Thrombocytosis cases had a higher prevalence of CH, with mutations in JAK2 and CALR associated with thrombocytosis.

HEMASPHERE (2023)

Article Hematology

In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype

Marieke J. A. Verhagen, Waander L. van Heerde, Johanna G. van der Bom, Erik A. M. Beckers, Nicole M. A. Blijlevens, Michiel Coppens, Samantha C. Gouw, Joop H. Jansen, Frank W. G. Leebeek, Lize F. D. van Vulpen, Danielle Meijer, Saskia E. M. Schols

Summary: The association between clinical bleeding phenotype and thrombin generation and plasmin generation profiles in patients with hemophilia was investigated. The study found that thrombin generation and plasmin generation parameters differed between patients with hemophilia and healthy individuals, and a decreased thrombin generation profile was associated with a severe clinical bleeding phenotype.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2023)

Article Oncology

Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population

Isabelle A. van Zeventer, Aniek O. de Graaf, Jonas B. Salzbrunn, Ilja M. Nolte, Priscilla Kamphuis, Avinash Dinmohamed, Bert A. van der Reijden, Jan Jacob Schuringa, Joop H. Jansen, Gerwin Huls

Summary: Knowledge about the evolution of clonal hematopoiesis is crucial for clinical decision-making. This study investigated clonal evolution in a large cohort and found that spliceosome and JAK2 mutations have the highest growth rates, while DNMT3A and TP53 mutations show minimal growth, regardless of cytosis or cytopenia. Individual variability suggests modulation by non-mutation-related factors. The risk for myeloid malignancy is highest for JAK2, spliceosome, or TP53 mutations and is preceded by cytosis or cytopenia. These findings provide important insights for monitoring and managing clonal hematopoiesis and related disorders.

CANCER CELL (2023)

Article Oncology

Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progression

Margot F. van Spronsen, Diana Hanekamp, Theresia M. Westers, Noortje van Gils, Eline Vermue, Arjo Rutten, Joop H. Jansen, Birgit I. Lissenberg-Witte, Linda Smit, Gerrit J. Schuurhuis, Arjan A. van de Loosdrecht

Summary: Myelodysplastic syndromes (MDS) are hematological disorders originating from neoplastic transformation of hematopoietic stem cells (HSCs). This study highlights the presence of immunophenotypic aberrant HSCs (IA-HSCs) in MDS-derived bone marrows (MDS-BMs), which predict leukemic progression and show potential as a prognostic biomarker. IA-HSCs are associated with perturbed hematopoiesis and independent of conventional risk factors. The sensitivity and specificity of IA-HSCs for predicting leukemic progression at 2 years follow-up were 83% and 71%, respectively.

LEUKEMIA (2023)

Letter Oncology

High expression of an intragenic long noncoding RNA misinterpreted as high FTO oncogene expression in NPM1 mutant acute myeloid leukemia

Saioa Arza-Apalategi, Branco M. H. Heuts, Meike T. M. Dooijes, Daan Gilissen, Adrian J. P. van der Heijden, Joop H. Jansen, Joost H. A. Martens, Bert A. van der Reijden

LEUKEMIA (2023)

Article Oncology

Radiotherapy in Combination with Systemic Therapy for Multiple Myeloma-A Critical Toxicity Evaluation in the Modern Treatment Era

Michael Oertel, Tom Schlusemann, Evgenii Shumilov, Gabriele Reinartz, Anne Bremer, Stephan Rehn, Georg Lenz, Cyrus Khandanpour, Hans Theodor Eich

Summary: This study evaluated the tolerability of concurrent radiotherapy and targeted therapy. The results showed that radiotherapy is safe and feasible in the treatment of multiple myeloma, but careful monitoring of potential toxicities is necessary.

CANCERS (2023)

Article Hematology

Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study

Stuart Scott, Richard Dillon, Christian Thiede, Sadia Sadiq, Ashley Cartwright, Hazel J. Clouston, Debbie Travis, Katya Mokretar, Nicola Potter, Andrew Chantry, Liam Whitby

Summary: The European LeukaemiaNet (ELN) MRD working group has published guidelines for standardizing molecular genetic MRD testing of certain markers. A study involving 29 international laboratories showed that most participants were able to accurately detect and interpret MRD testing results, although some errors were identified. False-positive results were reported in the NPM1 marker-negative samples, emphasizing the need for ongoing quality assessment and proficiency testing. The study also highlighted the need for revising the guidelines to address interpretive issues and improve dissemination.

BLOOD ADVANCES (2023)

Article Oncology

Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia

P. K. J. D. de Jonge, P. M. M. van Hauten, L. D. Janssen, A. L. de Goede, M. M. Berrien-Elliott, J. M. R. van der Meer, C. M. Mousset, M. W. H. Roeven, M. Foster, N. Blijlevens, W. Hobo, T. A. Fehniger, J. H. Jansen, N. P. M. Schaap, H. Dolstra

Summary: Allogeneic natural killer (NK) cell-based immunotherapy is a promising approach for acute myeloid leukemia (AML). A good manufacturing practice (GMP)-compliant, cytokine-based ex vivo manufacturing process for generating NK cells from CD34(+) hematopoietic stem and progenitor cells (HSPC) has been developed. This process generates a consistent and active NK cell product that meets the requirements for NK cell immunotherapy. The manufactured NK cell batches are used in a clinical trial approved by the Dutch Ethics Committee.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)

Article Biochemistry & Molecular Biology

Human CD34+-derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8+ T cell and NK cell responses in vitro and in vivo

Jesper van Eck van der Sluijs, Diede van Ens, Jolanda Brummelman, Daan Heister, Aastha Sareen, Lisa Truijen, Dorette S. van Ingen Schenau, Mirjam H. M. Heemskerk, Marieke Griffioen, Michel G. D. Kester, Nicolaas P. M. Schaap, Joop H. Jansen, Anniek B. van der Waart, Harry Dolstra, Willemijn Hobo

Summary: Non-DCs have been found to enhance the activation and expansion of antigen-specific CD8+ T cells mediated by DCs, without impairing the NK cell responses in vitro and in vivo. This provides a rationale for further clinical translation of the CD34+-derived DC-complete vaccine in hemato-oncology patients post alloSCT.

CELLULAR AND MOLECULAR LIFE SCIENCES (2023)

Article Oncology

Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial

Lisa B. Leypoldt, Maria Gavriatopoulou, Britta Besemer, Hans Salwender, Marc S. Raab, Axel Nogai, Cyrus Khandanpour, Volker Runde, Anna Jauch, Manola Zago, Peter Martus, Hartmut Goldschmidt, Carsten Bokemeyer, Meletios A. Dimopoulos, Katja C. Weisel

Summary: This study evaluated the safety and efficacy of daratumumab, bortezomib, and dexamethasone in multiple myeloma patients with severe renal function impairment. The treatment showed an overall response rate of 67% and improved renal function in patients. This study suggests that this treatment regimen could be considered in the clinical practice for multiple myeloma patients with severe renal function impairment.

CANCERS (2023)

暂无数据